FDA-approved1,2Evidence: Smaller human trialsCancer

Motixafortide1

Also called Aphexda1,2

Key takeaway

Motixafortide is a lab-made cyclic peptide that blocks the CXCR4 receptor. It is the active ingredient in Aphexda.1,2 Aphexda is approved, together with filgrastim (G-CSF), to move blood stem cells from the bone marrow into the bloodstream so they can be collected for a transplant of a patient’s own cells in multiple myeloma.1 In the randomized, placebo-controlled GENESIS trial of 122 patients described in the label, 67.5% given motixafortide and 9.5% given placebo reached the stem cell collection goal.1

Motixafortide at a glance

What it isA synthetic cyclic peptide that inhibits the chemokine receptor CXCR4, used to mobilize blood-forming stem cells, according to the Aphexda label.1
FDA statusFDA-approved. Drugs@FDA lists Aphexda, NDA 217159, with an original approval date of September 8, 2023. The cited label has no boxed warning.1,2
Human evidenceOne randomized, double-blind, placebo-controlled trial (GENESIS) in 122 patients with multiple myeloma, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is motixafortide?

Motixafortide is a synthetic cyclic peptide of 14 amino acids, including citrulline and a naphthylalanine, closed by a disulfide bond, according to the label.1

In the United States it is the active ingredient of Aphexda, approved under NDA 217159, according to Drugs@FDA.2

How does motixafortide work?

The label states that motixafortide blocks the CXCR4 receptor so that its signal, CXCL12, cannot bind. CXCR4 helps anchor blood-forming stem cells in the bone marrow, so blocking it releases them into the blood.1

What do human studies show?

GENESIS, described in the label, randomized 122 patients with multiple myeloma to motixafortide (80 patients) or placebo (42), all after several days of filgrastim.1

The collection goal was reached within up to two collection sessions by 67.5% of patients given motixafortide and 9.5% given placebo, according to the label.1

What the evidence base contains

  • Controlled human trial GENESIS (NCT03246529): a randomized, double-blind, placebo-controlled trial in 122 patients with multiple myeloma, all also given filgrastim, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is motixafortide FDA-approved?

Yes. Drugs@FDA lists Aphexda, application NDA 217159, with an original approval date of September 8, 2023.2

The Aphexda label cited here (DailyMed SPL version 3, published October 19, 2026) states that it is indicated in combination with filgrastim to mobilize blood stem cells for collection and transplant of a patient’s own cells in multiple myeloma.1

The label has no boxed warning. Its warnings include anaphylactic shock and other allergic reactions, which it states call for premedication and a setting where they can be treated, and the possibility of mobilizing leukemia cells.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Motixafortide is not among them.3,4

Timeline

  1. FDA approves Aphexda, NDA 217159, according to Drugs@FDA.2
  2. DailyMed publishes the Aphexda label version cited on this page.1

What is still unknown?

How it compares with other stem cell mobilizers: the trial described in the label compared it only with placebo, both added to filgrastim.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Motixafortide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Motixafortide are a bounded selection, not every registration or paper about Motixafortide. For the years before Motixafortide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Motixafortide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Motixafortide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Aphexda for stem cell mobilization in multiple myeloma. In a randomized, placebo-controlled trial of 122 patients described in the label, far more patients reached the stem cell collection goal with motixafortide. The label warns of anaphylactic shock.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Motixafortide?

FDA-approved as Aphexda for stem cell mobilization in multiple myeloma. In a randomized, placebo-controlled trial of 122 patients described in the label, far more patients reached the stem cell collection goal with motixafortide. The label warns of anaphylactic shock.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
5
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.↗Source date November 9, 2026
  2. Literature metadata · added November 16, 2026

    Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.↗Source date November 9, 2026
  3. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT06506461↗Source date October 15, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Motixafortide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

17Selected dated records
21Connected citations
5Populated source years2022–2026
3/4Record lanes present

Registered human studies

Trial composition

7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.

PhasesPhase 1 4Phase 2 2Phase 4 1
Status at observationRecruiting 4Completed 2Active, not recruiting 1

PubMed bibliography

Publication composition

9 of 9 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 9Clinical Trial, Phase II 3Multicenter Study 2Randomized Controlled Trial 2Research Support, Non-U.S. Gov't 2Clinical Trial, Phase I 1Clinical Trial, Phase III 1Comparative Study 1Equivalence Trial 1Research Support, N.I.H., Extramural 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
17

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 17 dated records

Research hub

Explore the Motixafortide evidence record

Open all 17 records →
17Dated records
3Evidence types
17Cited public sources
5Source years

Change ledger

Recently changed for Motixafortide

Open all 17 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT04543071

PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
September 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05618301

PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
August 11, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06442761

PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
September 8, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Motixafortide

Open the full research atlas →
PubMed9

9 with attributed title, venue, publication-date, and type metadata.

  1. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.Nature communications · 2026 08 21
  2. Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.Transfusion · 2026 07 11
  3. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.The oncologist · 2026 Mar 09
Explore all selected literature →
ClinicalTrials.gov7

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06506461Registry update October 15, 2026 · current at observation
  2. NCT04543071Registry update September 21, 2026 · current at observation
  3. NCT06442761Registry update September 8, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span April 1, 2022 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 17

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.↗

    PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.↗

    PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT06506461↗

    PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04543071↗

    PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06442761↗

    PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  6. Literature metadata

    Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.↗

    PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT07392970↗

    PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT07101445↗

    PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  9. Literature metadata

    Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.↗

    PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT06547112↗

    PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT05618301↗

    PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.↗

  12. Literature metadata

    Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.↗

    PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    APHEXDA (motixafortide) for injection · SPL version 3 · published 2026-10-19 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: APHEXDA (motixafortide acetate), NDA 217159 · original approval September 8, 2023 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026